Overview

Extension Study of Two Dosing Schedules of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
Extension Study of Two Dosing Schedules of Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Abbott
Treatments:
Adalimumab
Criteria
Inclusion Criteria:

- Subject participated and relapsed in prior PS study

Exclusion Criteria:

- Subject has other active skin diseases

- Multiple concomitant therapy restrictions and/or washouts (topicals, UV, other
systemic PS therapies)

- Poorly controlled medical conditions

- History of neurologic symptoms suggestive of central nervous system (CNS)
demyelinating disease.

- History of cancer or lymphoproliferative disease

- History of active TB or listeriosis, or persistent chronic or active infections

- Known to have immune deficiency or is immunocompromised

- Clinically significant abnormal laboratory test results

- Erythrodermic psoriasis or generalized pustular psoriasis